Oral Semaglutide Lowers HbA1c in Phase 3 Trial in Youth With Type 2 Diabetes

Novo Nordisk reported positive topline results from the Phase 3a PIONEER TEENS trial, suggesting that oral semaglutide may expand treatment options for children and adolescents aged 10 to 17 years with type 2 diabetes. According to the company, oral semaglutide reduced HbA1c by 0.83 percentage points more than placebo at 26 weeks in a 52-week randomized trial, with a safety profile described as consistent with prior semaglutide studies.¹

The finding is clinically relevant because pharmacologic options for youth-onset type 2 diabetes remain limited, and disease progression is often more aggressive than in adult-onset disease.

Phase 3a PIONEER TEENS Trial Finds Oral Semaglutide Lowers HbA1c in Adolescents With Type 2 Diabetes

“Over the past two decades, the prevalence of type 2 diabetes among children and adolescents has increased substantially, yet treatment options for this population remain limited, underscoring a significant unmet need,” Martin Holst Lange, MD, PhD, chief scientific officer and executive vice president of research and development at Novo Nordisk, said in the company announcement.¹

Novo Nordisk said it expects to file for a pediatric label expansion for oral semaglutide in the US and EU in the second half of 2026.

• PIONEER TEENS was a 52-week, randomized, double-blind, placebo-controlled Phase 3a study that enrolled 132 participants aged 10 to 17 years with type 2 diabetes.
• Patients received background therapy with metformin, basal insulin, or both, and were assigned to oral semaglutide at a maximum tolerated dose of 3 mg, 7 mg, or 14 mg once daily, or placebo.
• The primary end point was change in HbA1c from baseline to week 26.
• The company did not provide detailed secondary end point results, subgroup findings, or numerical safety event rates in the release.

Topline Results Highlight Potential New Option for Youth, Though Detailed Efficacy and Safety Data are Still Needed

At present, the topline disclosure limits independent interpretation. The reported HbA1c result suggests clinically meaningful glucose lowering, but the absence of full data on body weight, fasting glucose, treatment discontinuations, gastrointestinal adverse events, hypoglycemia, and week 52 durability makes it difficult to place the pediatric findings fully in context.

Peer-reviewed publication and presentation of detailed trial results will be important, particularly given adherence considerations associated with oral semaglutide administration requirements in adults.^2,3

Youth-onset type 2 diabetes is associated with early complications and substantial long-term cardiometabolic risk. Current management generally begins with lifestyle measures, metformin, and insulin when needed, while additional agents have gradually entered the pediatric landscape.⁴

The 2026 American Diabetes Association Standards of Care note the challenges of maintaining glycemic control in this population and support consideration of glucagon-like peptide 1 receptor agonists in appropriate patients.⁴ An oral formulation could be relevant for patients and families who prefer to avoid injections, although any such advantage would need to be weighed against tolerability, adherence, and cost.

Semaglutide is a glucagon-like peptide 1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. Oral semaglutide is already approved for adults with type 2 diabetes as Rybelsus in the US and EU, and prescribing information documents use as an adjunct to diet and exercise for glycemic control in adults.^2,3

The adult development program showed HbA1c lowering versus placebo and some active comparators, with gastrointestinal adverse effects typical of the class.⁵ Novo Nordisk also referenced cardiovascular benefit data for the molecule in adults,¹ but those findings should not be extrapolated to pediatric patients without direct evidence.

Findings Support Possible Pediatric Label Expansion

The pediatric result also arrives as interest in incretin-based therapies continues to grow across age groups. Still, clinicians will likely want to see whether efficacy was consistent across baseline therapies and whether gastrointestinal adverse events or treatment discontinuation affected real-world feasibility in adolescents. Regulatory review, if submitted as planned, will determine whether current evidence supports expansion into pediatric use.

For now, PIONEER TEENS adds an important data point to a treatment area with clear unmet need, but the topline nature of the report leaves several practical questions unanswered. Until full results are available, the trial should be viewed as promising but preliminary evidence for oral GLP-1 receptor agonist use in youth-onset type 2 diabetes.¹

References

1. Novo Nordisk. Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes. GlobeNewswire. April 23, 2026. Accessed April 23, 2026. https://www.globenewswire.com/news-release/2026/04/23/3279643/0/en/novo-nordisk-s-oral-semaglutide-demonstrates-potential-to-be-the-first-oral-glp-1-ra-therapy-for-children-and-adolescents-with-type-2-diabetes.html
2. Rybelsus (semaglutide) tablets [prescribing information]. US Food and Drug Administration. Revised 2024. Accessed April 2026.
3. European Medicines Agency. Rybelsus: summary of product characteristics. Accessed April 2026.
4. American Diabetes Association Professional Practice Committee. 14. Children and adolescents: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1):S297-S320.
5. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466-1480.